Umran Yaman

Umran Yaman

Auto-generated profile, based on publicly available information

Umran Yaman

UK Dementia Research Institute at UCL

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
SMSarah J. Marzi
Sarah J. Marzi
BSBrian M. Schilder
Brian M. Schilder
ANAlexi Nott
Alexi Nott
CFCarlo Sala Frigerio
Carlo Sala Frigerio
SWSandrine Willaime-Morawek
Sandrine Willaime-Morawek
DLDavid J. Llewellyn
David J. Llewellyn
INTRODUCTION: Experimental models are essential tools in neurodegenerative disease research. However, the translation of insights and drugs discovered in model systems has proven immensely challenging, marred by high failure rates in human clinical trials.METHODS: Here we review the application of artificial intelligence (AI) and machine learning (ML) in experimental medicine for dementia research.RESULTS: Considering the specific challenges of reproducibility and translation between other species or model systems and human biology in preclinical dementia research, we highlight best practices and resources that can be leveraged to quantify and evaluate translatability. We then evaluate how AI and ML approaches could be applied to enhance both cross‐model reproducibility and translation to human biology, while sustaining biological interpretability.DISCUSSION: AI and ML approaches in experimental medicine remain in their infancy. However, they have great potential to strengthen preclinical research and translation if based upon adequate, robust, and reproducible experimental data.Highlights: There are increasing applications of AI in experimental medicine. We identified issues in reproducibility, cross‐species translation, and data curation in the field. Our review highlights data resources and AI approaches as solutions. Multi‐omics analysis with AI offers exciting future possibilities in drug discovery.

9 January 2025 in Brain
Verified
Journal Article
Open access
AGAndrew C Graham
Andrew C Graham
EBEftychia Bellou
Eftychia Bellou
JHJanet Harwood
Janet Harwood
UYUmran Yaman
Umran Yaman
MCMeral Celikag
Meral Celikag
DSDervis A Salih
Dervis A Salih
Ageing underlies functional decline of the brain and is the primary risk factor for several neurodegenerative conditions, including Alzheimer’s disease (AD). However, the molecular mechanisms that cause functional decline of the brain during ageing, and how these contribute to AD pathogenesis, are not well understood. The objective of this study was to identify biological processes that are altered during ageing in the hippocampus and that modify Ad risk and lifespan, and then to identify putative gene drivers of these programmes. We integrated common human genetic variation associated with human lifespan or Ad from genome-wide association studies with co-expression transcriptome networks altered with age in the mouse and human hippocampus. Our work confirmed that genetic variation associated with Ad was enriched in gene networks expressed by microglia responding to ageing and revealed that they were also enriched in an oligodendrocytic gene network. Compellingly, longevity-associated genetic variation was enriched in a gene network expressed by homeostatic microglia whose expression declined with age. The genes driving this enrichment include CASP8 and STAT3, highlighting a potential role for these longevity-associated genes in the homeostatic functions of innate immune cells, and these genes might drive ‘inflammageing’. Thus, we observed that gene variants contributing to ageing and AD balance different aspects of microglial and oligodendrocytic function. Furthermore, we also highlight putative Ad risk genes, such as LAPTM5, ITGAM and LILRB4, whose association with Ad falls below genome-wide significance but show strong co-expression with known Ad risk genes in these networks. Indeed, five of the putative risk genes highlighted by our analysis, ANKH, GRN, PLEKHA1, SNX1 and UNC5CL, have subsequently been identified as genome-wide significant risk genes in a subsequent genome-wide association study with larger sample size, validating our analysis. This work identifies new genes that influence ageing and AD pathogenesis, and highlights the importance of microglia and oligodendrocytes in the resilience of the brain against ageing and AD pathogenesis. Our findings have implications for developing markers indicating the physiological age of the brain and new targets for therapeutic intervention.

27 June 2024 in F1000Research
Verified
Journal Article
Open access
PDF file
SDSontosh K Deb
Sontosh K Deb
DKDivya Kalra
Divya Kalra
JKJędrzej Kubica
Jędrzej Kubica
ESErik Stricker
Erik Stricker
VTVan Q. Truong
Van Q. Truong
BBBen Busby
Ben Busby
Background The goal of the Fifth Annual Baylor College of Medicine & DNAnexus Structural Variation Hackathon was to push forward the research on structural variants (SVs) by rapidly developing and deploying open-source software. The event took place in-person and virtually in August 2023, when 49 scientists from 14 countries and 8 U.S. states collaboratively worked on projects to address critical gaps in the field of genomics. The hackathon projects concentrated on developing bioinformatic workflows for the following challenges: RNA transcriptome comparison, simulation of mosaic variations, metagenomics, Mendelian variation, SVs in plant genomics, and assembly vs. mapping SV calling comparisons. Methods As a starting point we used publicly available data from state-of-the-art long- and short-read sequencing technologies. The workflows developed during the hackathon incorporated open-source software, as well as scripts written using Bash and Python. Moreover, we leveraged the advantages of Docker and Snakemake for workflow automation. Results The results of the hackathon consists of six prototype bioinformatic workflows that use open-source software for SV research. We made the workflows scalable and modular for usability and reproducibility. Furthermore, we tested the workflows on example public data to show that the workflows can work. The code and the data produced during the event have been made publicly available on GitHub (https://github.com/collaborativebioinformatics) to reproduce and built upon in the future. Conclusions The following sections describe the motivation, lessons learned, and software produced by teams during the hackathon. Here, we describe in detail the objectives, value propositions, implementation, and use cases for our workflows. In summary, the article reports the advancements in the development of software for SV detection made during the hackathon.

7 November 2025 in F1000Research
Verified
Journal Article
Open access
PDF file
FJFarhang Jaryani
Farhang Jaryani
BABishnu Adhikari
Bishnu Adhikari
SBShaghayegh Beheshti
Shaghayegh Beheshti
SFSarah Fross
Sarah Fross
JKJęDrzej Kubica
JęDrzej Kubica
BBBen Busby
Ben Busby
Background Structural variants (SVs) and metagenomics remain challenging areas in genomics, requiring new tools and collaborative solutions. Hackathons provide a rapid, team-based approach to prototyping and innovation. Methods In August 2024, 48 scientists from six continents convened at Baylor College of Medicine for the Sixth Structural Variant Codeathon. Participants worked in interdisciplinary teams over three days, using public datasets and cloud-based infrastructure to design and implement computational tools. Results Eight projects were developed, addressing topics such as tandem repeat annotation, structural variant discovery, benchmarking, pangenome visualization, and machine learning applications. Each project produced open-source software, with repositories openly available on GitHub and archived on Zenodo. Conclusions The hackathon fostered global collaboration and generated reproducible, community-driven tools. These outputs provide new resources for structural variation and metagenomics research and demonstrate the effectiveness of hackathons in advancing genomic science.

3 April 2023 in medRxiv
Verified
Preprint
Open access
PDF file
AGAndrew C. Graham
Andrew C. Graham
EBEftychia Bellou
Eftychia Bellou
JHJanet Harwood
Janet Harwood
UYUmran Yaman
Umran Yaman
MCMeral Celikag
Meral Celikag
DSDervis A Salih
Dervis A Salih
Ageing is the greatest global healthcare challenge, as it underlies age-related functional decline and is the primary risk factor for a range of common diseases, including neurodegenerative conditions such as Alzheimer’s disease (AD). However, the molecular mechanisms defining chronological age versus biological age, and how these underlie AD pathogenesis, are not well understood. The objective of this study was to integrate common human genetic variation associated with human lifespan or AD from Genome-Wide Association Studies (GWAS) with co-expression networks altered with age in the central nervous system, to gain insights into the biological processes which connect ageing with AD and lifespan. Initially, we identified common genetic variation in the human population associated with lifespan and AD by performing a gene-based association study using GWAS data. We also identified preserved co-expression networks associated with age in the brains of C57BL/6J mice from bulk and single-cell RNA-sequencing (RNA-seq) data, and in the brains of humans from bulk RNA-seq data. We then intersected the human gene-level common variation with these co-expression networks, representing the different cell types and processes of the brain. We found that genetic variation associated with AD was enriched in both microglial and oligodendrocytic bulk RNA-seq gene networks, which show increased expression with ageing in the human hippocampus, in contrast to synaptic networks which decreased with age. Further, longevity-associated genetic variation was modestly enriched in a single-cell gene network expressed by homeostatic microglia. Finally, we performed a transcriptome-wide association study (TWAS), to identify and confirm new risk genes associated with ageing that show variant-dependent changes in gene expression. In addition to validating known ageing-related genes such as APOE and FOXO3, we found that Caspase 8 (CASP8) and APOC1 show genetic variation associated with longevity. We observed that variants contributing to ageing and AD balance different aspects of microglial function suggesting that ageing-related processes affect multiple cell types in the brain. Specifically, changes in homeostatic microglia are associated with lifespan, and allele-dependent expression changes in age-related genes control microglial activation and myelination influencing the risk of developing AD. We identified putative molecular drivers of these genetic networks, as well as module genes whose expression in relevant human tissues are significantly associated with AD-risk or longevity, and may drive “inflammageing.” Our study also shows allele-dependent expression changes with ageing for genes classically involved in neurodegeneration, including MAPT and HTT, and demonstrates that PSEN1 is a prominent member/hub of an age-dependent expression network. In conclusion, this work provides new insights into cellular processes associated with ageing in the brain, and how these may contribute to the resilience of the brain against ageing or AD-risk. Our findings have important implications for developing markers indicating the physiological age and pre-pathological state of the brain, and provide new targets for therapeutic intervention.

10 August 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
UYUmran Yaman
Umran Yaman
GBGareth Banks
Gareth Banks
EGEmil K. Gustavsson
Emil K. Gustavsson
PMPaige Mumford
Paige Mumford
NMNaciye Magusali
Naciye Magusali
DSDervis A. Salih
Dervis A. Salih
Genome-wide association studies (GWAS) have identified a transcriptional network of Alzheimer’s disease (AD) risk genes that are primarily expressed in microglia and are associated with AD pathology. However, traditional short-read sequencers have limited our ability to fully characterize how GWAS variants exert their effects on gene expression regulation or alternative splicing in response to the pathology, particularly resulting in inaccurate detection of splicing. To address this gap, we utilized long-read RNA-sequencing (RNA-seq) in the App NL-G-F knock-in mouse model to identify changes in splicing and novel transcript isoforms in response to amyloid-β. We show that long-read RNA-seq can recapitulate the expected induction of microglial expressed risk genes such as Trem2 in response to amyloid-β at 9 months of age associated with ageing-dependent deficiencies in spatial short-term memory in the App NL-G-F knock-in mice. Our results not only identified novel splicing events and transcript isoform abundance in genes associated with AD, but also revealed the complex regulation of gene expression through splicing in response to amyloid plaques. Surprisingly, the regulation of alternative splicing in response to amyloid was seen in genes previously not identified as AD risk genes, expressed in microglia, neurons and oligodendrocytes, and included genes such as Syngr1 that modulate synaptic physiology. We saw alternative splicing in genes such as Ctsa , Clta , Dennd2a , Irf9 and Smad4 in mice in response to amyloid, and the orthologues of these genes also showed transcript usage changes in human AD brains. Our data suggests a model whereby induction of AD risk gene expression associated with microglial proliferation and activation is concomitant with alternative splicing in a different class of genes expressed by microglia and neurons, which act to adapt or preserve synaptic activity in response to amyloid-β during early stages of the disease. Our study provides new insights into the mechanisms and effects of the regulation of genes associated with amyloid pathology, which may ultimately enable better disease diagnosis, and improved tracking of disease progression. Additionally, our findings identify new therapeutic avenues for treatment of AD.